CD276 and esophageal cancer: B7-H3 reportedly both activates and inhibits T cell responses [15, 16], and may also promote disease progression in pancreatic carcinoma [17], hepatocellular cancer [18], human esophageal cancer [19], non-small cell lung cancer [20], prostate cancer [21], endometrial cancer [22], and gastric cancer [2].